Cited 0 times in
Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.